Abstract
The design and synthesis of a novel series of Rev-erbα agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erbα agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Brain / drug effects
-
Brain / metabolism
-
Injections, Intraperitoneal
-
Isoquinolines / chemical synthesis
-
Isoquinolines / chemistry*
-
Isoquinolines / pharmacokinetics
-
Naphthalenes / chemical synthesis*
-
Naphthalenes / chemistry
-
Naphthalenes / pharmacokinetics
-
Nuclear Receptor Subfamily 1, Group D, Member 1 / agonists*
-
Nuclear Receptor Subfamily 1, Group D, Member 1 / metabolism
-
Rats
-
Structure-Activity Relationship
Substances
-
Isoquinolines
-
Naphthalenes
-
Nuclear Receptor Subfamily 1, Group D, Member 1